company background image
TECH

Bio-TechneNasdaqGS:TECH Stock Report

Market Cap

US$21.1b

7D

-3.3%

1Y

109.8%

Updated

27 Sep, 2021

Data

Company Financials +
TECH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends0/6

TECH Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide.

Bio-Techne Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Techne
Historical stock prices
Current Share PriceUS$511.45
52 Week HighUS$242.03
52 Week LowUS$543.85
Beta1.13
1 Month Change3.32%
3 Month Change14.21%
1 Year Change109.83%
3 Year Change150.96%
5 Year Change366.40%
Change since IPO19,859.02%

Recent News & Updates

Shareholder Returns

TECHUS Life SciencesUS Market
7D-3.3%0.8%0.1%
1Y109.8%56.4%35.3%

Return vs Industry: TECH exceeded the US Life Sciences industry which returned 56.4% over the past year.

Return vs Market: TECH exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is TECH's price volatile compared to industry and market?
TECH volatility
TECH Beta1.13
Industry Beta0.97
Market Beta1

Stable Share Price: TECH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: TECH's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19762,600Chuck Kummethhttps://www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
TECH fundamental statistics
Market CapUS$21.14b
Earnings (TTM)US$140.32m
Revenue (TTM)US$931.03m

143.0x

P/E Ratio

21.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TECH income statement (TTM)
RevenueUS$931.03m
Cost of RevenueUS$296.62m
Gross ProfitUS$634.42m
ExpensesUS$494.09m
EarningsUS$140.32m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)3.58
Gross Margin68.14%
Net Profit Margin15.07%
Debt/Equity Ratio22.3%

How did TECH perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

35%

Payout Ratio

Valuation

Is Bio-Techne undervalued compared to its fair value and its price relative to the market?

143.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TECH ($538.88) is trading above our estimate of fair value ($350.68)

Significantly Below Fair Value: TECH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TECH is poor value based on its PE Ratio (150.7x) compared to the US Life Sciences industry average (53.1x).

PE vs Market: TECH is poor value based on its PE Ratio (150.7x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: TECH is poor value based on its PEG Ratio (7x)


Price to Book Ratio

PB vs Industry: TECH is overvalued based on its PB Ratio (13.5x) compared to the US Life Sciences industry average (6.1x).


Future Growth

How is Bio-Techne forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

21.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TECH's forecast earnings growth (21.5% per year) is above the savings rate (2%).

Earnings vs Market: TECH's earnings (21.5% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TECH's revenue (14.1% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: TECH's revenue (14.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (19.9%).


Past Performance

How has Bio-Techne performed over the past 5 years?

18.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TECH has a large one-off loss of $77.2M impacting its June 30 2021 financial results.

Growing Profit Margin: TECH's current net profit margins (15.1%) are lower than last year (31%).


Past Earnings Growth Analysis

Earnings Trend: TECH's earnings have grown by 18.8% per year over the past 5 years.

Accelerating Growth: TECH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TECH had negative earnings growth (-38.7%) over the past year, making it difficult to compare to the Life Sciences industry average (56.9%).


Return on Equity

High ROE: TECH's Return on Equity (8.9%) is considered low.


Financial Health

How is Bio-Techne's financial position?


Financial Position Analysis

Short Term Liabilities: TECH's short term assets ($510.6M) exceed its short term liabilities ($152.3M).

Long Term Liabilities: TECH's short term assets ($510.6M) do not cover its long term liabilities ($539.4M).


Debt to Equity History and Analysis

Debt Level: TECH's debt to equity ratio (22.3%) is considered satisfactory.

Reducing Debt: TECH's debt to equity ratio has increased from 11.1% to 22.3% over the past 5 years.

Debt Coverage: TECH's debt is well covered by operating cash flow (100.7%).

Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (18.3x coverage).


Balance Sheet


Dividend

What is Bio-Techne current dividend yield, its reliability and sustainability?

0.25%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TECH's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.33%).

High Dividend: TECH's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (3.6%).


Stability and Growth of Payments

Stable Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TECH is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TECH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Chuck Kummeth (61 yo)

8.42yrs

Tenure

US$15,889,897

Compensation

Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M...


CEO Compensation Analysis

Compensation vs Market: Chuck's total compensation ($USD15.89M) is above average for companies of similar size in the US market ($USD11.36M).

Compensation vs Earnings: Chuck's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: TECH's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: TECH's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TECH insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bio-Techne Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Techne Corporation
  • Ticker: TECH
  • Exchange: NasdaqGS
  • Founded: 1976
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$21.145b
  • Shares outstanding: 39.24m
  • Website: https://www.bio-techne.com

Number of Employees


Location

  • Bio-Techne Corporation
  • 614 McKinley Place N.E.
  • Minneapolis
  • Minnesota
  • 55413
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 22:21
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.